People
For PE sponsors, compliance gaps destroy exit value, not through deal failure but by constraining leverage, widening escrows, deferring consideration, and weakening bidder tension at the precise moment when value should be crystallized.
Compliance becomes decisive for value realization and execution risk at exit, directly shaping pricing, leverage, and the certainty of closing a deal.
In competitive sale processes, compliance gaps surface during confirmatory diligence and trigger predictable outcomes: expanded diligence scope, tighter representations and warranties, increased escrows or indemnities, delayed signing, or repricing. The frequency with which compliance issues underpin Warranty & Indemnity claims underscores the pattern: apparently contained risks convert into tangible economic loss after headline value is agreed.
Compliance readiness directly shapes exit economics – price realization, structure, timing, and execution certainty – determining whether value accrues to the sponsor or is defensively reallocated to buyers, lenders, and insurers.
Why compliance tolerance collapses at exit
At exit, buyers and lenders underwrite not just the asset, but the transfer of risk itself. Compliance issues that may have been consciously tolerated during the hold, often labelled “known and contained”, become transaction-critical once warranties are signed, financing is committed, and liability shifts to the buyer.
Even contained or historic issues trigger friction during confirmatory diligence, widening scope and driving demand for governance comfort and remediation evidence, particularly in regulated or cross-border contexts, where lender scrutiny intensifies. The result is rarely outright deal failure, but a progressive erosion of negotiating leverage: timelines extend, bidder tension softens, and value is defended through structure rather than price.
Why baseline compliance no longer passes exit scrutiny
The standard of what buyers and lenders consider exit-ready compliance has materially shifted. Compliance is no longer assessed against historical adherence, but against whether the asset can credibly withstand current and forward-looking regulatory, geopolitical, and technological risk scenarios without impairing deal certainty, financing capacity, or lender underwriting assumptions.
Trade and tariff regimes, export controls, sanctions, and supply-chain resilience now directly affect cost structures and sourcing models. These aspects are explicitly stress-tested during buyer and lender due diligence. Exposures translate into underwriting assumptions, leverage tolerance, and covenant structures, making compliance posture a determinant of both pricing and structure at exit.
Technology-related compliance risk has become particularly consequential because it is difficult or impossible to remediate once a sale process or financing discussion is underway.
Data privacy gaps, cybersecurity vulnerabilities, cross-border data transfer issues, and AI governance uncertainty cannot be evidenced, contained, or fixed within deal timelines. This gap typically becomes visible only during confirmatory diligence, when timelines are compressed and residual uncertainty is priced defensively, through extended escrows, reduced leverage, or deferred consideration rather than headline valuation adjustments.
How compliance gaps destroy deal value
Compliance gaps rarely crystallize as explicit line-item deductions. More often, they erode value indirectly but decisively by weakening exit optionality, delaying liquidity, and shifting negotiating leverage precisely when outcomes are meant to be locked in. When issues surface late in confirmatory diligence or regulatory review, sponsors lose control over timing and narrative, the two most powerful levers in any sale process.
An example is Exactech, a US-based orthopedic medical device manufacturer acquired by TPG Capital in 2018. Between 2021 and 2022, three to four years into the hold, Exactech initiated large-scale FDA-related recalls after defective product packaging was found to compromise implant safety. The quality control failures were not identified during entry diligence, nor systematically monitored during the hold period.
By the time recalls were initiated, the resulting regulatory exposure and more than 2,500 product-liability lawsuits had rendered conventional exit routes effectively unfinanceable. By October 2024, Exactech entered Chapter 11, substituting a sponsor-led exit with a court-supervised restructuring. Had compliance readiness been assessed 18–24 months before the planned exit window, the quality control exposure could have been identified, remediated, or factored into exit strategy and timing.
The Exactech case illustrates a critical pattern: compliance gaps that emerge late in the hold eliminate financeable exit structures. Lenders underwriting leveraged buyouts require demonstrable compliance governance to justify debt multiples and covenant flexibility. When quality control failures, regulatory breaches, or litigation exposure surface during lender due diligence, debt commitments shrink or disappear entirely. For sponsors, this translated into impaired DPI (Distributions to Paid-In Capital), extended hold periods beyond fund life, and a collapse of financeable exit options, destroying value that no operational improvement could offset.
Strategic transactions demonstrate the same mechanics. In Verizon's acquisition of Yahoo's core assets in 2016, late-stage disclosure of historic data breaches led to a $350 million purchase-price reduction. Similarly, Microsoft's acquisition of Activision Blizzard faced prolonged regulatory scrutiny, extending timelines and requiring late-stage structural remedies before closing in October 2023. Across these cases, the failure was not strategy or operating performance. It was a misalignment between compliance risk and buyer, lender, or regulator tolerance at exit.
When compliance weaknesses thin the bidder universe
Compliance risk manifests as transaction friction. Weaknesses in anticorruption frameworks, data privacy, ESG reporting, or internal controls surface during diligence and ripple through representations and warranties, indemnity negotiations, and financing approval processes, narrowing the universe of buyers and lenders willing to underwrite the asset.
Buyers respond by expanding diligence scope and seeking additional contractual protection through escrows, caps, and survival periods. In parallel, lenders reassess downside exposure, often tightening terms, reducing leverage multiples, or conditioning commitments on incremental comfort letters, third party opinions, or remediation milestones. The cumulative effect is fewer clean exit options, longer processes, and defensive value protection that shifts economics away from the sponsor.
What exit-ready compliance looks like
Exit-ready compliance is not about perfection. It is about predictability, credibility with lenders, and transaction certainty at the point of exit.Prudent sponsors therefore enter the sale process with a clear, diligence-ready fact base: documented governance, explicit ownership, and evidence that known issues are identified, prioritized, and under control. This allows buyer questions to be answered precisely, issues to be framed on the sponsor's terms, and prevents uncertainty dominating the narrative.
In practice, sponsors ensure exit-ready compliance by establishing a structured fact base 18 to 24 months pre-exit, using internal reviews, management attestations, targeted deep-dives, and Compliance Health Checks. These efforts should concentrate on exit-critical criteria:
- Issue inventory, severity, and exit impact
This provides a deal-grade view of material compliance risks, quantifying escrow exposure, indemnity caps, and leverage constraints, with resolution timelines tied to the exit window. - Demonstrable remediation
Evidence is gathered to show that controls are implemented and operating effectively, supported by documentation that withstands buyer and lender confirmatory diligence. - Buyer and lender underwrite-ability
Stress-testing establishes whether residual compliance risk supports target debt multiples and minimizes escrow/indemnity drag on proceeds, modeling how specific gaps (data privacy breaches, sanctions exposure, product liability) affect leverage, covenant flexibility, and cash-to-equity. - Diligence-ready narrative
A consistent, fact-based storyline for each known issue(root cause, actions taken, residual risk, and why it is bounded)enables alignment across management messaging, vendor diligence, and the data room.
What sponsors should do now
Sponsors planning exits in the next 18 to 24 months should treat compliance readiness as a critical exit-preparation workstream:
- Compliance health checks 18 to 24 months pre-exit
Run structured diagnostics covering regulatory exposure, data governance, ESG frameworks, anticorruption controls, and sector-specific risk (FDA/EMA for MedTech, AML/sanctions for FinTech, export controls for industrials), mapping the findings to leverage impact, escrow exposure, and underwrite-ability. - Remediation prioritized by exit economics
Focus resources on issues affecting financing terms, bidder universe, or indemnity negotiations. Build a fact-based narrative demonstrating control, ownership, and bounded residual risk. - Lender-grade stress testing before launch
Model how compliance gaps affect debt multiples, covenant packages, and cash proceeds. Lock-in financing certainty before entering the sale process. - Diligence-ready documentation
Prepare a compliance fact base that answers buyer and lender questions precisely, on sponsor terms – before RFPs (Requests for Proposal) are issued.
Sponsors that execute this preparation defend exit value, preserve competitive tension, and realize returns on their terms. Those that defer compliance readiness to the sale process risk seeing value discounted through extended escrows, reduced leverage, deferred consideration, or sub-optimal exit structures. Precisely when years of value creation are meant to be monetized.
AlixPartners works with PE sponsors to build diligence-ready compliance fact bases that preserve exit value and financing certainty. Our approach combines targeted compliance health checks, lender-grade stress testing of leverage impact, and focused remediation in sectors where regulatory and operational risk converge, including MedTech, FinTech, industrials, and cross-border transactions. We help sponsors prepare well ahead of launch, ensuring compliance gaps are identified, quantified, and remediated before they reshape exit economics or erode negotiating leverage.
Find out more about our article series:
